Enochian Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark R. Dybul
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Century City Medical Plaza Los Angeles CA United States of America 90067-2012
- IPO Date
- Feb 7, 2018
- CIK
- 0001527728
- Website
- enochianbio.com
- Similar Companies
- Business
- Enochian Biosciences, Inc. (ENOB) is a clinical-stage biotechnology company focused on developing curative therapies for infectious diseases and cancer. The company advances gene and cell therapies targeting HIV/AIDS, hepatitis B virus (HBV), and hepatocellular carcinoma (HCC), including proprietary platforms such as ENOB-HV-01 for latent HIV reservoir elimination; ENOB-DC vaccine for inducing immune responses against HBV and HCC; and ENOB-LHV-04/05 for enhancing T-cell function in HIV patients. It also develops novel lipid nanoparticle (LNP) delivery systems for genetic medicines and immune therapies like EN340 for HBV cure and EN858 for HCC immunotherapy; operations span preclinical and clinical trials primarily in the United States with international collaboration potential. Founded in 2017 and headquartered in Los Angeles, California, Enochian Biosciences maintains a lean structure without notable subsidiaries or parent entities, targeting patient populations in virology and oncology segments. Recent developments include progression of ENOB-HV-01 into Phase 1 clinical trials for HIV functional cure and strategic advancements in LNP technology partnerships, reflecting ongoing expansions in its curative therapy pipeline within the last two years.
3 Doomed Biotech Stocks Destined for Disaster
ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action – ENOB
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ENOB
'Murder-For-Hire Conspiracy': Why Enochian Biosciences Stock Is Plunging
ENOB Stock Gains 20% Following Founder Arrest, Hindenburg Short
6 Stocks Halted In Wednesday's Session: Here's Why
ENOB Stock: Why The Price Increased Today
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
Enochian Biosciences: A Follow Through For An HIV Cure
Why Enochian BioSciences Was a Winner on Monday
Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology